Delivery Order SPE2DB22D3010-SPE2DB25FP2ZS
- Not listed
- The Defense Logistics Agency awarded a $31.8K delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of June 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $5,249.48 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of RINVOQ ER 15 MG tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a performance completion date of August 19, 2025. AmerisourceBergen Drug Corp will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary...
- The Defense Logistics Agency awarded a delivery order valued at $26,154.99 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30-unit bottles). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $22,157.82 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 4, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $53,675.87 to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count packages) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, valued at $7,057.46, for the supply of RINVOQ ER 30 mg tablets (30-count units). This non-set-aside, competitively awarded contract utilizes firm fixed pricing and carries an ultimate completion date of June 20, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters operations. This delivery order is issued...
- The Defense Logistics Agency awarded a $23,543.70 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and is scheduled for completion by September 17, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a $197,052.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for RINVOQ ER 15 mg tablets (30-count units). This is a non-set-aside competitive award with an ultimate completion date of September 18, 2025, to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $13,070.59 delivery order to AmerisourceBergen Drug Corp on June 13, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This competitive award utilizes firm fixed pricing with a completion date of June 16, 2025, and carries no set-aside designation. The delivery order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a delivery order valued at $12,446.64 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP2ZSDelivery Order
The Defense Logistics Agency awarded a $20,968.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a non-set-aside competitive award with an ultimate completion date of July 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as the comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor headquartered in Pennsylvania, with an extensive portfolio of competitively awarded contracts supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's demonstrated capability to fulfill federal medical supply requirements through open competition, combined with its expansive IDC with the DLA, positions it as a key supplier for the military's pharmaceutical and medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.0k | 7/21/25 |